Drugs / Ceftobiprole
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Refused (EMA) | EU (EMA) | Zeftera (previously Zevtera) | — | 2010-09-16 | europa.eu ↗ |
Trials 15 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 19 trials | ||||||
| Phase 1 | NCT06808646 | Jan → Feb 2025 | — | Basilea Pharmaceutica | Completed | No outcome recorded |
| Phase 1 | NCT00771524 | Apr 2009 → Feb 2010 | — | Basilea Pharmaceutica | Completed | No outcome recorded |
| Phase 1 | NCT00965042 | Apr → May 2009 | — | Basilea Pharmaceutica | Completed | No outcome recorded |
| Phase 1 | NCT00770978 | Nov 2008 → Sep 2010 | — | Basilea Pharmaceutica | Completed | No outcome recorded |
| Phase 1 | NCT00771719 | Oct 2008 → Nov 2009 | — | Basilea Pharmaceutica | Terminated | No outcome recorded |
| Phase 1 | NCT01026558 | Aug → Nov 2007 | obesity disorder, staphylococcal infection, streptococcal infection | Basilea Pharmaceutica | Completed | No outcome recorded |
| Phase 1 | NCT01026636 | Aug 2007 → Apr 2010 | staphylococcal infection, streptococcal infection | Basilea Pharmaceutica | Completed | No outcome recorded |
| Phase 1 | NCT01026740 | Jun → Sep 2007 | staphylococcal infection, streptococcal infection | Basilea Pharmaceutica | Completed | No outcome recorded |
| Phase 1 | NCT01030731 | May → Aug 2007 | staphylococcal infection, streptococcal infection | Basilea Pharmaceutica | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00505258 | ? → Apr 2009 | bacterial infectious disease | Basilea Pharmaceutica | Withdrawn | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT05856227 | Aug 2023 → Dec 2024 | neonatal sepsis | Basilea Pharmaceutica | Completed | No outcome recorded |
| Phase 3 | NCT00529282 | Oct 2007 → Jan 2008 | Pseudomonas infection, gram-positive bacterial infections, neutropenia | Basilea Pharmaceutica | Terminated | No outcome recorded |
| Phase 3 | NCT00229008 | Nov 2005 → May 2007 | pneumonia | Basilea Pharmaceutica | Completed | No outcome recorded |
| Phase 3 | NCT00210964 | Apr 2005 → May 2007 | pneumonia | Basilea Pharmaceutica | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT04171674 | Apr 2021 → Jan 2023 | pneumonia | Nîmes University Hospital | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 16 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ceftobiprole | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06808646 ↗ |
| Known as | ceftobiprole medocaril | “This was a multicenter, open-label, single-arm, multiple-dose study of intravenous (IV) ceftobiprole medocaril (prodrug of the active moiety ceftobiprole).” NCT05856227 ↗3“Ceftobiprole medocaril is a cephalosporin antibiotic with anti-MRSA (Methicillin-Resistant Staphylococcus aureus) activity.” NCT00505258 ↗ “Ceftobiprole medocaril (the water-soluble prodrug \[form\] of ceftobiprole) referred to as ceftobiprole” NCT00210964 ↗ “Ceftobiprole, the active moiety of ceftobiprole medocaril, is a novel broad-spectrum cephalosporin” PMID 24723282 ↗ Apr 2014 |
| Action | Inhibit | “This study assessed whether there was an inhibitory effect of ceftobiprole on hepatic organic anion-transporting polypeptide 1B (OATP1B) activity.” NCT06808646 ↗ |
| Modality | Small molecule | “Ceftobiprole, the active moiety of ceftobiprole medocaril, is a novel broad-spectrum cephalosporin” PMID 24723282 ↗ Apr 2014 |
| Route | Intravenous | “Patients will receive either ceftobiprole plus placebo or a comparator by intravenous infusion” NCT00210964 ↗ |